Health Catalyst Closes Vitalware Divestiture and Retires $160 Million in Debt to Refocus on Healthcare Intelligence

Health Catalyst (搜索)搜索该公司, Inc. (Nasdaq: HCAT), a healthcare intelligence company, reported that it closed the divestiture of its Vitalware (搜索)搜索该词条 revenue cycle management (RCM) business on July 31, 2026, and used the proceeds to fully repay its credit facility debt, marking a decisive step in the company's multiyear transformation under its Project Nexus strategic initiative.

"Vitalware (搜索)搜索该词条 is a strong business, but it sits outside our highest conviction technology opportunities," said Ben Albert, Chief Executive Officer of Health Catalyst (搜索)搜索该公司, explaining the decision to divest the business to retire debt. The company divested Vitalware to Med-Metrix (搜索)搜索该词条 for $147 million in total cash consideration, resulting in net proceeds of $145.5 million after transaction costs.

Debt Repayment and Balance Sheet Transformation

Health Catalyst (搜索)搜索该公司 used the divestiture proceeds together with cash on hand to fully retire approximately $160 million in credit facility debt plus accrued interest and prepayment premium. Going forward, this eliminates approximately $19 million of annual interest expense on a GAAP basis and approximately $16.5 million of annual cash interest payments, based on annualizing the first half of 2026.

On a pro forma basis, giving effect to the transaction and the credit facility repayment, the company would have ended the quarter with cash, cash equivalents, and short-term investments of approximately $82 million and zero debt. The company also has a transition services agreement in place with Med-Metrix (搜索)搜索该词条 for up to six months, which will provide a modest income offset during that period.

CFO Jason Alger noted that significant investment would have been required to grow the Vitalware (搜索)搜索该词条 business, which "would have negatively impacted adjusted EBITDA and placed pressure on the company's ability to meet debt covenants."

Second Quarter 2026 Financial Results

For the second quarter ended June 30, 2026, Health Catalyst (搜索)搜索该公司 reported total revenue of $70.5 million, a 13% decrease from $80.7 million in the prior-year period, but exceeding the high end of its guided range of $68 million to $70 million. Technology revenue was $48.8 million, reflecting an 8% decrease from $52.9 million, while professional services revenue was $21.7 million, a 22% decrease from $27.8 million.

Adjusted EBITDA for the quarter was $9.9 million, compared to $9.3 million in the second quarter of 2025, coming in at the high end of the guided range of $9 million to $10 million. Adjusted gross margin was 51%, compared to 50% in the prior-year period. Adjusted technology gross margin was 63%, down from 66%, reflecting costs associated with migrating clients to the Ignite (搜索)搜索该靶点 platform and deployment costs incurred prior to revenue recognition. Adjusted professional services gross margin improved to 22% from 18%.

Adjusted operating expenses were $25.9 million, representing 37% of revenue, compared to $30.6 million, or 38% of revenue, in the prior-year period. On a GAAP basis, the company reported a net loss of $40.5 million, compared to a net loss of $41.0 million in the prior-year period.

Platform Migration and Churn Dynamics

The company continues to work through revenue headwinds related to its migration from the legacy DOS (Data Operating System) platform to the Ignite (搜索)搜索该靶点 architecture. Health Catalyst (搜索)搜索该公司 had previously identified $12.5 million of notified Annual Recurring Revenue (ARR) down-sell and churn related to the migration, along with approximately $52 million of additional at-risk ARR, of which management expected to retain $22 million.

Alger stated, "we continue to see significant pressure in this area," referring to the client-by-client retention work being performed during the migration. Management expects to be generally through the platform migration-related churn headwinds by the end of 2027.

Updated Guidance

As a result of the divestiture, Health Catalyst (搜索)搜索该公司 updated its full-year 2026 outlook to total revenue of $246 million to $249 million and adjusted EBITDA of $18 million to $18.5 million. The largest single driver of the guidance update is the removal of Vitalware (搜索)搜索该词条's revenue and adjusted EBITDA contribution following the July 31 close, reflecting the removal of five months of Vitalware revenue.

For the third quarter of 2026, the company expects total revenue of $55 million to $56 million and adjusted EBITDA of breakeven to $500,000. Vitalware (搜索)搜索该词条 was a higher adjusted EBITDA margin business, with first-half 2026 adjusted EBITDA of $11.4 million.

On the services front, management now anticipates exiting the year at the lower end of the previously discussed range, closer to $55 million in services revenue annually, as clients continue to bring certain managed services work back in-house. The company is holding its full-year bookings target of $22 million to $26 million, which includes Vitalware (搜索)搜索该词条 bookings through the transaction date.

Strategic Focus on Intelligence Products

Albert emphasized that health systems are facing structural challenges, including eroding margins and rising labor costs, which increases the urgency for intelligence products that reduce expenses. "We believe our deep domain expertise and 18 years of improvement data position us well to address these pressing areas of need through our intelligence products," Albert said.

The company is prioritizing target investments in new products and the proprietary intelligence layer they are built on, AI-driven automation and efficiency initiatives, and the continued build-out of its Ignite (搜索)搜索该靶点 and interoperability platform. Management expects overall adjusted gross margin to trend higher over the long term as the revenue mix continues to shift toward technology.